ES2113094T3 - Las microparticulas macromoleculares y metodos de obtencion. - Google Patents

Las microparticulas macromoleculares y metodos de obtencion.

Info

Publication number
ES2113094T3
ES2113094T3 ES94910826T ES94910826T ES2113094T3 ES 2113094 T3 ES2113094 T3 ES 2113094T3 ES 94910826 T ES94910826 T ES 94910826T ES 94910826 T ES94910826 T ES 94910826T ES 2113094 T3 ES2113094 T3 ES 2113094T3
Authority
ES
Spain
Prior art keywords
microparticles
obtaining
methods
dehydrating agent
microparticle composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94910826T
Other languages
English (en)
Inventor
James E Woiszwillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epic Therapeutics Inc
Original Assignee
Epic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epic Therapeutics Inc filed Critical Epic Therapeutics Inc
Application granted granted Critical
Publication of ES2113094T3 publication Critical patent/ES2113094T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA COMPOSICION DE MICROPARTICULAS MACROMOLECULARES FORMADA A BASE DE DESHIDRATAR UNA SOLUCION ACUOSA DE MACROMOLECULAS Y ENTRECRUZAR LAS MACROMOLECULAS DESHIDRATADAS CON UN AGENTE ENTRECRUZADOR MIENTRAS SE ENCUENTRA EN UNA FASE LIQUIDA O CON CALOR. PREFERENTEMENTE, EL AGENTE DESHIDRATADOR ES UNA MEZCLA POLIMERICA DE POLIVINILPIRROLIDONA Y POLIETILENGLICOL, EL REACTIVO ENTRECRUZADOR ES UN GLUTARALDEHIDO Y LA MACROMOLECULA ES UNA PROTEINA, PREFERENTEMENTE UNA INMUNOGLOBULINA. TAMBIEN SE PRESENTAN METODOS PARA SU USO CON FINES DE INVESTIGACION, DIAGNOSTICO Y TERAPEUTICOS.
ES94910826T 1993-03-09 1994-03-04 Las microparticulas macromoleculares y metodos de obtencion. Expired - Lifetime ES2113094T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2823793A 1993-03-09 1993-03-09

Publications (1)

Publication Number Publication Date
ES2113094T3 true ES2113094T3 (es) 1998-04-16

Family

ID=21842313

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94910826T Expired - Lifetime ES2113094T3 (es) 1993-03-09 1994-03-04 Las microparticulas macromoleculares y metodos de obtencion.
ES97112821T Expired - Lifetime ES2215207T3 (es) 1993-03-09 1994-03-04 Microparticulas de macromoleculas y metodos de produccion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES97112821T Expired - Lifetime ES2215207T3 (es) 1993-03-09 1994-03-04 Microparticulas de macromoleculas y metodos de produccion.

Country Status (11)

Country Link
US (1) US5578709A (es)
EP (2) EP0809110B1 (es)
JP (5) JPH08507806A (es)
AT (2) ATE258685T1 (es)
AU (1) AU6358594A (es)
CA (1) CA2157793C (es)
DE (2) DE69408527T2 (es)
DK (1) DK0809110T3 (es)
ES (2) ES2113094T3 (es)
PT (1) PT809110E (es)
WO (1) WO1994020856A1 (es)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
WO1996020012A2 (en) * 1994-12-23 1996-07-04 Middlesex Sciences, Inc. Methods for preparing and purifying macromolecular conjugates
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
CN100457188C (zh) * 1998-03-06 2009-02-04 生物领域医疗公司 用于组织膨胀和治疗的可植入颗粒
US6660301B1 (en) 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US6270700B1 (en) 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
FR2784580B1 (fr) 1998-10-16 2004-06-25 Biosepra Inc Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
EP1074248A1 (en) * 1999-07-08 2001-02-07 Arnold Hilgers Delivery system for biological material
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6822086B1 (en) * 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
AU4724401A (en) 2000-02-28 2001-09-12 Genesegues Inc Nanocapsule encapsulation system and method
US7338657B2 (en) * 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
US6436424B1 (en) * 2000-03-20 2002-08-20 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
WO2001070289A2 (en) 2000-03-20 2001-09-27 Biosphere Medical, Inc. Injectable and swellable microspheres for tissue bulking
ES2551164T3 (es) 2000-03-24 2015-11-16 Biosphere Medical, Inc. Microesferas para embolización activa
CA2424896A1 (en) 2000-10-06 2002-04-11 Jagotec Ag A controlled-release, parenterally administrable microparticle preparation
SE517422C2 (sv) * 2000-10-06 2002-06-04 Bioglan Ab Farmaceutiskt acceptabel stärkelse
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
ES2326209T3 (es) 2000-10-27 2009-10-05 Baxter Healthcare S.A. Produccion de microesferas.
SE518008C2 (sv) * 2000-11-16 2002-08-13 Bioglan Ab Parenteralt administrerbara mikropartiklar och förfarande för framställning av desamma
SE518007C2 (sv) 2000-11-16 2002-08-13 Bioglan Ab Förfarande för framställning av mikropartiklar
US20070142325A1 (en) * 2001-01-08 2007-06-21 Gustavsson Nils O Starch
JP4799749B2 (ja) * 2001-03-29 2011-10-26 花王株式会社 樹脂複合体
ES2622468T3 (es) * 2001-03-29 2017-07-06 Synergy Pharmaceuticals, Inc. Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis
WO2002100444A1 (en) * 2001-06-08 2002-12-19 Biosphere Medical Inc. Colloidal metal labelled microparticles, their production and use
US20030064033A1 (en) * 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
US7105181B2 (en) 2001-10-05 2006-09-12 Jagotec, Ag Microparticles
SE0201599D0 (sv) 2002-03-21 2002-05-30 Skyepharma Ab Microparticles
US7053134B2 (en) * 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
EP1555938A4 (en) * 2002-06-21 2010-11-03 Reuven Avrahom Cyrulnik METHOD AND SYSTEM FOR IMAGING MACROMOLECULES
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
JP2007531701A (ja) * 2003-07-18 2007-11-08 バクスター・インターナショナル・インコーポレイテッド 制御された相分離により調製される小球状粒子の作製方法、使用および組成物
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
CA2532874A1 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
US9176121B2 (en) * 2004-02-13 2015-11-03 Roche Diagnostics Hematology, Inc. Identification of blood elements using inverted microscopy
ES2313350T3 (es) 2004-05-12 2009-03-01 Baxter International Inc. Microesferas de acido nucleico, produccion y suministro de las mismas.
DK1758558T3 (da) * 2004-05-12 2014-01-20 Baxter Int Oligonukleotidholdige mikrokugler samt deres anvendelse til fremstilling af et medikament til behandling af diabetes type 1
MXPA06012992A (es) * 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
KR20140090270A (ko) 2005-05-09 2014-07-16 바이오스피어 메디칼 에스.에이. 마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및 방법
US8017152B2 (en) * 2005-05-27 2011-09-13 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
ES2691646T3 (es) 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US20070191272A1 (en) * 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20070081972A1 (en) * 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
CN101511170B (zh) * 2005-12-22 2014-03-26 奥克伍德药业有限公司 可升华持续释放传递***和其制造方法
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
JP5457680B2 (ja) 2006-01-24 2014-04-02 アンサン バイオファーマ，インコーポレイテッド 高分子マイクロスフェアの調製技術
WO2007090127A2 (en) 2006-01-30 2007-08-09 Surgica Corporation Compressible intravascular embolization particles and related methods and delivery systems
US20080039890A1 (en) * 2006-01-30 2008-02-14 Surgica Corporation Porous intravascular embolization particles and related methods
JP2007279028A (ja) * 2006-03-13 2007-10-25 Mitsubishi Chemicals Corp 孔を有する生体物質構造体及びその製造方法、並びに、それを用いた生体物質担持体、対象物質の精製方法、アフィニティークロマトグラフィー用容器、分離用チップ、対象物質の解析方法、対象物質の解析用分離装置、及びセンサーチップ
EP2944382A1 (en) 2006-04-26 2015-11-18 Micell Technologies, Inc. Coatings containing multiple drugs
AU2007281737B2 (en) 2006-08-04 2013-09-19 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
AU2008242842B2 (en) 2007-04-17 2014-06-05 Baxter Healthcare Sa Nucleic acid microparticles for pulmonary delivery
US20090098110A1 (en) * 2007-05-30 2009-04-16 Duke University Injectable forms of solid-forming crosslinked bioelastic biopolymers for local drug delivery
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
PL2014280T3 (pl) 2007-07-13 2015-04-30 Cc Ery Gmbh Mikrocząsteczki, substytut krwi i sposób ich formowania
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
EA201000646A1 (ru) * 2007-10-15 2010-10-29 Байоджен Айдек Эмэй Инк. Способ получения биопрепарата (варианты)
US8506933B2 (en) * 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
EP2271294B1 (en) 2008-04-17 2018-03-28 Micell Technologies, Inc. Stents having bioabsorbable layers
WO2009129544A1 (en) 2008-04-18 2009-10-22 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CN104491864A (zh) 2008-04-21 2015-04-08 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物及方法
US9602777B2 (en) 2008-04-25 2017-03-21 Roche Diagnostics Hematology, Inc. Systems and methods for analyzing body fluids
WO2012030313A1 (en) 2008-04-25 2012-03-08 James Winkelman Method of determining a complete blood count and a white blood cell differential count
WO2009149278A1 (en) * 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
AU2009270849B2 (en) 2008-07-17 2013-11-21 Micell Technologies, Inc. Drug delivery medical device
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
EP2306975A4 (en) 2008-07-21 2012-10-31 Otonomy Inc CONTROLLED RELEASE COMPOSITIONS MODULATING THE OTIC STRUCTURE AND MODULATING THE NATURAL IMMUNE SYSTEM AND METHODS OF TREATING OTIC DISORDERS
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
JP2012507562A (ja) * 2008-10-30 2012-03-29 ダビド リウ 微小球性多孔質生体適合性足場並びにその製造方法及び装置
CA2994066A1 (en) * 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
ES2730800T3 (es) * 2009-02-03 2019-11-12 Amunix Pharmaceuticals Inc Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
WO2010120552A2 (en) 2009-04-01 2010-10-21 Micell Technologies, Inc. Coated stents
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
AU2010313456A1 (en) 2009-10-30 2012-05-17 Ntf Therapeutics, Inc. Improved neurturin molecules
CA2781664A1 (en) * 2009-11-27 2011-06-03 Msdx, Inc. Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6393037B2 (ja) 2010-09-15 2018-09-19 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤および使用方法
US9111343B2 (en) 2011-01-18 2015-08-18 Roche Diagnostics Hematology, Inc. Microscope slide coordinate system registration
US8673309B2 (en) 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
SI3564260T1 (sl) 2012-02-15 2023-02-28 Bioverativ Therapeutics Inc. Sestavki faktorja VIII in postopki njegove izdelave in uporabe
US20140099380A1 (en) 2012-06-28 2014-04-10 Ansun Biopharma, Inc. Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture
US9730885B2 (en) 2012-07-12 2017-08-15 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
JP6145513B2 (ja) * 2012-11-15 2017-06-14 ユタ−イナ ディーディーエス アンド アドバンスト セラピューティクス リサーチ センター アルブミン及びデキストランサルフェートを含む抗癌剤吸着能力の向上された生分解性マイクロビーズ及びその製造方法
CN104994841B (zh) 2012-11-27 2018-11-16 犹他-仁荷Dds及新医疗技术开发共同研究所 包含阴离子性高分子的抗癌药吸附能力得到提高的生物降解性微珠及其的制备方法
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6169255B2 (ja) 2013-05-02 2017-07-26 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリアリールエーテルスルホンコポリマー
JP2016519965A (ja) 2013-05-15 2016-07-11 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
SG10201902499VA (en) 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
EP3303585A4 (en) 2015-06-03 2018-10-31 Board of Regents of the University of Nebraska Dna editing using single-stranded dna
CA2993645A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
AU2017290256A1 (en) 2016-06-29 2019-01-17 Otonomy, Inc. Triglyceride otic formulations and uses thereof
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
WO2021076794A1 (en) 2019-10-15 2021-04-22 Cornell University Methods for modulating level of expression from gene therapy expression cassette
JP2023500793A (ja) 2019-10-16 2023-01-11 コーネル・ユニバーシティー アルツハイマー病に対する遺伝子治療方法
WO2021086973A2 (en) 2019-10-28 2021-05-06 University Of Iowa Research Foundation Formulation for delivery of lubricin gene
EP4065600A1 (en) 2019-11-25 2022-10-05 Cornell University Apoe gene therapy
WO2021216547A1 (en) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
EP4138921A1 (en) 2020-04-23 2023-03-01 University Of Iowa Research Foundation Gper proteolytic targeting chimeras
US20230293678A1 (en) 2020-08-21 2023-09-21 Aliasger K. Salem Cationic nanoparticle adjuvants
WO2022047201A1 (en) 2020-08-27 2022-03-03 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
WO2022125963A1 (en) 2020-12-11 2022-06-16 University Of Iowa Research Foundation Compositions comprising molecules for cystic fibrosis treatment
WO2022246280A1 (en) 2021-05-21 2022-11-24 University Of Iowa Research Foundation Anti-oxidant containing particles and methods of use
WO2022271951A1 (en) 2021-06-23 2022-12-29 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137631A (en) * 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3663687A (en) * 1968-06-26 1972-05-16 Minnesota Mining & Mfg Biodegradable parenteral microspherules
BE789195A (fr) * 1971-09-24 1973-03-22 Gist Brocades Nv Compositions d'enzymes
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4115534A (en) * 1976-08-19 1978-09-19 Minnesota Mining And Manufacturing Company In vitro diagnostic test
US4169804A (en) * 1976-08-19 1979-10-02 Minnesota Mining And Manufacturing Company Magnetically responsive composite microparticle
CH621479A5 (es) * 1977-08-05 1981-02-13 Battelle Memorial Institute
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
JPS5719660A (en) * 1980-07-09 1982-02-01 Fuji Photo Film Co Ltd Microcapsule for immune reaction
JPS5951355A (ja) * 1982-09-17 1984-03-24 Fujirebio Inc 抗ウイルス抗体検出用試薬
US5141738A (en) * 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US4794000A (en) * 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
SE459005B (sv) * 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
SE462894B (sv) * 1985-10-28 1990-09-17 Biogram Ab Mikrokapslar, foerfarande foer framstaellning daerav samt anvaendning
JPS6317904A (ja) * 1986-07-09 1988-01-25 Mitsubishi Chem Ind Ltd 多孔質架橋ポリビニルアルコ−ル粒子の製造法
JPS6377821A (ja) * 1986-09-19 1988-04-08 Teikoku Seiyaku Kk 安定なプロスタグランジンｅ組成物
IL83451A (en) * 1987-08-06 1991-06-10 Univ Ramot Stabilized water soluble enzymes and a method for their preparation
CA2023803C (en) * 1989-08-23 1999-05-18 Takeshi Miyazaki Method for measuring an immunologically active material and apparatus suitable for practicing said method
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5525519A (en) * 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use

Also Published As

Publication number Publication date
EP0688429B1 (en) 1998-02-11
JPH08507806A (ja) 1996-08-20
DE69433523T2 (de) 2004-12-23
DE69408527T2 (de) 1998-06-04
JP2007297633A (ja) 2007-11-15
WO1994020856A1 (en) 1994-09-15
JP2004323528A (ja) 2004-11-18
PT809110E (pt) 2004-06-30
DK0809110T3 (da) 2004-05-24
ES2215207T3 (es) 2004-10-01
ATE163230T1 (de) 1998-02-15
AU6358594A (en) 1994-09-26
ATE258685T1 (de) 2004-02-15
EP0809110B1 (en) 2004-01-28
CA2157793C (en) 1999-07-13
US5578709A (en) 1996-11-26
DE69408527D1 (de) 1998-03-19
EP0688429A1 (en) 1995-12-27
EP0809110A1 (en) 1997-11-26
JP2006023297A (ja) 2006-01-26
JP2007212464A (ja) 2007-08-23
DE69433523D1 (de) 2004-03-04
CA2157793A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
ES2113094T3 (es) Las microparticulas macromoleculares y metodos de obtencion.
ZA803599B (en) Method for cross linking polymers,polymer compositions and uses thereof
DE3583560D1 (de) Polymerisationsverfahren und polymerzusammensetzungen.
DE69033460D1 (de) Vernetzter polymerelektrolyt und verfahren zu seiner herstellung
BR8008412A (pt) Polimero, processo para sua preparacao, diaminas, e aplicacao dos ditos polimeros
NL185069C (nl) Gevormd, uit meer dan een laag bestaand, metaal/polymeersamenstel en vormbaar samenstel.
BR9814374B1 (pt) "urÉias heterocÍclicas substituÍdas e composiÇÕes compreendendo as mesmas"
FR2542000B1 (fr) Nouveaux derives de l'ethanol, leur preparation et leur utilisation comme fongicides
OA06146A (fr) N-phényl-N'-(2'-chloro-6-fluoro-benzoyl)-urées, leur procédé de production et leur application comme insecticides.
NO870684D0 (no) Nye polymerer og kryssbundne sammensetninger fremstilt derav.
DE69106656T2 (de) Tanninextrakt von Kastanienholz, Verfahren zu deren Herstellung und deren Verwendung.
DE68916399D1 (de) Lösungsmittelfreier festes Polymerelektrolyt und Verfahren zu seiner Herstellung.
DE69318946D1 (de) Biologisch abbaubares, optisch aktives Lactonpolymer und Verfahren zu seiner Herstellung
DE68914321T2 (de) Lichtabschwächer und Verfahren zu seiner Herstellung.
DE69121005D1 (de) Zusammensetzung zur Vernetzung von Äthylenpolymeren, Verfahren zur Vernetzung von Äthylenpolymeren und vernetzbare Zusammensetzung
BE882420A (fr) Nouveaux derives d'alpha-(3,4-dichlorophenyl)-imidazoline ou pyrimidine-2-methanols utiles notamment comme agents antisecretoires et leur procede de preparation
ATE121420T1 (de) Verfahren zur herstellung von 3-(l-pyroglutamyl)- l-thiazolidin-4-carbonsäure-derivaten.
BE862663A (fr) Nouvelles phenylcarbamoyl-2-pyrazolines substituees, leur procede de preparation et leur application comme insecticides
FR2340927A1 (fr) Nouveaux derives de chloral, leur procede de preparation et leur application comme fongicides
BE834222A (fr) Nouveaux derives d'uree, leur procede de preparation et leur application comme fongicides
FR2446279B1 (fr) Cis- et trans-3-aryloxy-4-hydroxypyrrolidines et leurs derives, utiles notamment en medecine veterinaire comme antidepresseurs
FR2304603A1 (fr) Nouvelles 2,3-dihalogeno-alcanoyl-urees, leur procede de preparation et leur application comme fongicides
OA05562A (fr) Nouveaux imidazolyl-O, N-acétals acylés, leur procédé de préparation et leur application comme fongicides.
AT369390B (de) Verfahren zur herstellung von wasserloeslichen, insbesondere als flockungsmittel verwendbaren organischen polymeren
OA06145A (fr) Nouveaux carbamoyl-triazolyl-O,N-acétals, leur procédé de production et leur application comme fongicides.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 688429

Country of ref document: ES